BMW Q2 Profit Jumps 26 Per Cent, Boosted by Record Car Sales
Frankfurt: German luxury carmaker BMW AG said its second-quarter operating profit rose 26 per cent, above forecasts, as new off road models and strong China sales boosted earnings.Â
Sales of BMW branded cars rose 8.3 per cent to 458,000 units - a record high - thanks to a jump in sales in China and Europe and the rollout of new models such as the 4-series coupe and the 2-series compact. Earnings before interest and tax of 2.6 billion euros ($3.5 billion) topped a forecast of 2.23 billion in a Reuters poll of analysts helped by new models, the company said.
"This is a major beat and we remain convinced that the street is underestimating BMW's medium and long-term earnings power," ISI Group said in a note on Tuesday.
BMW's automotive EBIT margin, the best gauge to compare profitability with peers, was 11.7 per cent, higher than the 7.9 per cent achieved by rival Mercedes-Benz Cars and above its own target range of between 8 per cent and 10 per cent.
"The BMW Group increased sales volume, revenues and Group earnings in both the second quarter and the six-month reporting periods, continuing the successful development of our business," chief executive Norbert Reithofer said in a statement.
Munich-based BMW aims to achieve a significant rise in sales volume in 2014 to 2 million or more, after it delivered a record 1.96 million Mini, Rolls Royce and BMW cars in 2013. BMW also targets a rise in pre-tax profits of up to 10 per cent for 2014, the company reiterated.
Last year, BMW led with 1.65 million BMW branded cars sold worldwide, topping Audi at 1.57 million and Daimler in third with 1.47 million Mercedes-Benz-branded cars sold.
($1 = 0.7450 euros)
Copyright: Thomson Reuters 2014
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets